BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986322
Other: Placebo for BMS-986322

First Posted Date: 2022-09-19

Last Posted Date: 2023-06-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT05546151

Locations: 🇺🇸
Anaheim Clinical Trials Llc, Anaheim, California, United States

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: Advanced Solid Tumors
Non-small Cell Lung Cancer

Interventions: Biological: BMS-986442
Biological: Nivolumab
Drug: Docetaxel
Drug: Carboplatin
Drug: Pemexetred
Drug: Paclitaxel

First Posted Date: 2022-09-16

Last Posted Date: 2024-10-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT05543629

Locations: 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸
Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
🇺🇸
Local Institution - 0096, Costa Mesa, California, United States

and more 29 locations

A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants

Completed

Conditions: Healthy Participants

First Posted Date: 2022-09-14

Last Posted Date: 2022-12-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 10

Registration Number: NCT05539976

Locations: 🇺🇸
Local Institution - 0001, Woburn, Massachusetts, United States

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

Early Phase 1

Terminated

Conditions: Healthy Participants

Interventions: Drug: BMS-986421
Other: Placebo

First Posted Date: 2022-08-26

Last Posted Date: 2023-09-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 46

Registration Number: NCT05517837

Locations: 🇺🇸
Local Institution - 0001, Cypress, California, United States

Study of Relatlimab in Combination With Nivolumab in Chinese Participants

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Biological: Relatlimab
Biological: Nivolumab

First Posted Date: 2022-08-12

Last Posted Date: 2024-02-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 6

Registration Number: NCT05498480

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

Phase 2

Withdrawn

Conditions: Melanoma
Urothelial Carcinoma

Interventions: Drug: Nivolumab/rHuPH20
Drug: Nivolumab

First Posted Date: 2022-08-11

Last Posted Date: 2023-04-14

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT05496192

Locations: 🇩🇪
Local Institution - 0001, Berlin, Germany
🇪🇸
Local Institution - 0002, Sevilla, Spain
🇩🇪
Local Institution - 0020, Essen, North Rhine-Westphalia, Germany

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Recruiting

Conditions: Obstructive Hypertrophic Cardiomyopathy

Interventions: Drug: Non-mavacamten symptomatic oHCM therapy
Drug: Mavacamten

First Posted Date: 2022-08-05

Last Posted Date: 2024-12-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1600

Registration Number: NCT05489705

Locations: 🇦🇹
Local Institution - 0087, Graz, Austria
🇦🇹
Local Institution - 0082, Braunau am Inn, Austria
🇦🇹
Local Institution - 0088, Innsbruck, Austria

and more 95 locations

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Phase 4

Completed

Conditions: Psoriasis

Interventions: Drug: Deucravacitinib
Other: Placebo

First Posted Date: 2022-07-28

Last Posted Date: 2024-11-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 152

Registration Number: NCT05478499

Locations: 🇺🇸
Local Institution - 0001, Hot Springs, Arkansas, United States
🇺🇸
Local Institution - 0007, Indianapolis, Indiana, United States
🇺🇸
Local Institution - 0041, Louisville, Kentucky, United States

and more 26 locations

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

Phase 2

Completed

Conditions: Crohn Disease

Interventions: Drug: Ozanimod

First Posted Date: 2022-07-22

Last Posted Date: 2024-11-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5

Registration Number: NCT05470985

Locations: 🇺🇸
Local Institution - 0008, Seattle, Washington, United States
🇺🇸
Local Institution - 0010, Garden Grove, California, United States
🇺🇸
Local Institution - 0071, Lebanon, New Hampshire, United States

and more 43 locations

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Phase 2

Active, not recruiting

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Oral Azacitidine
Drug: Placebo for Oral Azacitidine

First Posted Date: 2022-07-22

Last Posted Date: 2024-08-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 230

Registration Number: NCT05469737

Locations: 🇺🇸
Local Institution - 0073, Pittsburgh, Pennsylvania, United States
🇭🇰
Local Institution - 0180, Shatin, Hong Kong
🇯🇵
Local Institution - 0154, Sapporo, Hokkaido, Japan

and more 62 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy